Clinical trial · Interventional
IMRT Lower Limb Soft Tissue Sarcoma
A Phase II Study of Preoperative Intensity-Modulated Radiation Therapy For Lower Limb Soft Tissue Sarcoma
NCT00188175CI-TRIAL-00014767completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Intensity-modulated radiation therapy may make wound healing problems less likely by 1)precisely shaping the region of high radiation dose to the shape of the tissue which harbours tumour cells, and 2) precisely shaping the regions of low radiation dose to the shapes of the normal tissues which are more sensitive to radiation effects.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Sarcoma | Sarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Intensity Modulated Radiation Therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- IMRT for lower limb soft tissue sarcoma
- interventionNames
- Radiation: Intensity Modulated Radiation Therapy
Primary outcomes (1)
- measure
- Major wound complications within 120 days following surgery
- timeFrame
- 120 days post-op
Secondary outcomes (1)
- measure
- Assess acute and late radiation toxicity including limb edema
- timeFrame
- up to120 days
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically proven soft tissue sarcoma * Lesion lies between the iliac crest (hipbone) and the ankle * Lesion is newly diagnosed * Assessed by radiation oncologist and surgical oncologist Exclusion Criteria: * Benign histologies * Histologies generally treated with chemotherapy * Prior or recurrent cancer, except nonmelanomatous skin cancer or carcinoma in-situ of the cervix
References
Publications (0)
Data not yet available
No reference posted for this study.